Skip directly to content

Safety Information


Indications and Clinical Use:

  • ELIQUIS is indicated for the prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective knee or hip replacement surgery.
  • ELIQUIS is indicated for the prevention of stroke and systemic embolism in patients with atrial fibrillation.

Not recommended in children.


  • Clinically significant active bleeding, including gastrointestinal bleeding
  • Lesions or conditions at increased risk of clinically significant bleeding
  • Hepatic disease associated with coagulopathy and clinically relevant bleeding risk
  • Concomitant systemic treatment with strong inhibitors of both CYP3A4 and P-glycoprotein
  • Concomitant treatment with any other anticoagulant including unfractionated heparin, except at doses used to maintain a patent central venous or arterial catheter, low molecular weight heparins, such as enoxaparin and dalteparin, heparin derivatives, such as fondaparinux, and oral anticoagulants, such as warfarin, dabigatran, rivaroxaban, except under circumstances of switching therapy to or from apixaban

Most serious warnings and precautions:

  • Bleeding: if severe, discontinue
  • Peri-operative spinal/epidural anesthesia, lumbar puncture: increased risk of hematoma
  • INR monitoring: not a valid measure to assess anticoagulant activity of ELIQUIS

Other relevant warnings and precautions:

  • Caution when used with drugs that affect hemostasis
  • Not recommended in patients with prosthetic heart valves or with hemodynamically significant rheumatic heart disease, especially mitral stenosis
  • Avoid use with strong inducers of both CYP 3A4 and P-gp
  • Caution in patients with mild or moderate hepatic impairment (not recommended if severe) or elevated liver enzymes
  • Pre-operative/post-operative considerations
  • Renal impairment: not recommended if creatinine clearance <15 mL/min or dialysis; dosing adjustments may be required; renal function should be monitored
  • Not recommended in pregnant or nursing women
  • Hip fracture surgery patients

For more information:

Please consult the product monograph by clicking here for important information relating to adverse reactions, drug interactions, and dosing information.

The product monograph is also available by calling 1-866-463-6267.

ELIQUIS is a trade-mark of Bristol-Myers Squibb Company used under license by Bristol-Myers Squibb Canada.